You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

LKB1-inactive adenocarcinoma

Showing 1 - 25 of 2,918
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced LKB1-inactive Lung Adenocarcinoma Trial in Milan (Metformin Hydrochloride, Cisplatin, Carboplatin)

Recruiting
  • Advanced LKB1-inactive Lung Adenocarcinoma
  • Metformin Hydrochloride
  • +5 more
  • Milan, Italy
    Marina Chiara Garassino
Nov 12, 2020

Lung Cancer Trial in Houston (Cemiplimab, Kevzara (Sarilumab))

Not yet recruiting
  • Lung Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2023

Non Small Cell Lung Cancer Trial in Mexico City (Metformin Hydrochloride, Placebo)

Recruiting
  • Non Small Cell Lung Cancer
  • Metformin Hydrochloride
  • Placebo
  • Mexico City, Mexico
    Instituto Nacional de Cancerologia
Jul 21, 2022

NSCLC With STK11/LKB1 Mutation Trial in New York (Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication,

Not yet recruiting
  • Non-small Cell Lung Cancer With STK11/LKB1 Mutation
  • Daratumumab and Hyaluronidase-fihj
  • +2 more
  • New York, New York
    NYU Langone Health
Mar 29, 2023

Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))

Not yet recruiting
  • Gastric Adenocarcinoma
  • cadonilimab combined +paclitaxel (albumin-bound)
  • (no location specified)
Nov 1, 2023

Local and Peripheral Immune Responsive Landscape Induced by

Not yet recruiting
  • Lung Adenocarcinoma
  • Local Cryoablation
    • (no location specified)
    Oct 24, 2023

    Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

    Not yet recruiting
    • Gastric
    • Colorectal Adenocarcinoma
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital & Institute
    Nov 1, 2023

    HER-2 Expression in Pancreatic Duct Adenocarcinoma

    Completed
    • Pancreatic Adenocarcinoma
    • immunohistochemical approach
    • (no location specified)
    Sep 20, 2023

    Tumor Size and Prognosis in Small Bowel adenocarcinoma-a

    Completed
    • Prognosis
    • no interventions
    • Dalian, Liaoning, China
      Dalian Third People's Hospital Affiliated to Dalian Medical Univ
    Oct 11, 2023

    Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)

    Not yet recruiting
    • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
    • (no location specified)
    Jul 17, 2023

    Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction Trial in Guangzhou (Docetaxel for injection (Albumin-bound),

    Recruiting
    • Gastric Adenocarcinoma
    • Adenocarcinoma of Gastroesophageal Junction
    • Docetaxel for injection (Albumin-bound)
    • Taxotere
    • Guangzhou, China
      Ethics Committee of Sun-Yat-Sen University Cancer Center
    Jan 27, 2023

    HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

    Not yet recruiting
    • HER2-positive Advanced Gastric Cancer
    • HER2-positive Gastroesophageal Junction Adenocarcinoma
    • Trastuzumab deruxtecan
    • (no location specified)
    Aug 11, 2023

    Metabolism Trial in Austin (12 hours of physical inactivity, 24 hours of physical inactivity, 36 hours of physical inactivity)

    Not yet recruiting
    • Metabolism
    • 12 hours of physical inactivity
    • +2 more
    • Austin, Texas
      The University of Texas at Austin
    Sep 13, 2023

    NSCLC (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors Trial in Irving, San Antonio,

    Not yet recruiting
    • Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors
    • Assigned interventions
    • Irving, Texas
    • +2 more
    Nov 7, 2023

    Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

    Not yet recruiting
    • Adenocarcinoma - GEJ
    • Gastric Adenocarcinoma
    • (no location specified)
    Sep 26, 2023

    Moderate Plaque Psoriasis Trial in Miami, Houston, San Antonio (Guselkumab, Placebo)

    Recruiting
    • Moderate Plaque Psoriasis
    • Miami, Florida
    • +3 more
    Sep 9, 2023

    Stomach Tumors Trial in Shanghai (Fruquintinib, Sintilimab)

    Active, not recruiting
    • Stomach Neoplasms
    • Shanghai, China
      Renji Hospital
    Apr 3, 2023

    Gastric Cancer, GastroEsophageal Cancer, Fruquintinib Trial in Nanning (Fruquintinib + SOX)

    Recruiting
    • Gastric Cancer
    • +3 more
    • Fruquintinib + SOX
    • Nanning, China
      Guangxi Medical University Cancer Hospital
    Dec 2, 2022

    Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)

    Not yet recruiting
    • Esophagogastric Adenocarcinoma
    • Sacituzumab govitecan
    • (no location specified)
    Nov 9, 2023

    Pancreatic Cancer Trial in Sydney, Wollongong, Melbourne (Durvalumab, Oxaliplatin, Irinotecan)

    Recruiting
    • Pancreatic Cancer
    • Sydney, New South Wales, Australia
    • +2 more
    Oct 19, 2023

    Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction Trial in Germany (5-Fluorouracil,

    Active, not recruiting
    • Esophageal Adenocarcinoma (UICC TNM7)
    • Adenocarcinoma of the Esophagogastric Junction
    • Aachen, Germany
    • +29 more
    Nov 1, 2022

    Calprotectin and Ischemia Modified Albumin Serum to Measure

    Completed
    • Behçet's Diseasecases
    • Serum calprotectin and IMA concentrations
    • Mansoura, Egypt
      Mansoura University Hospital
    May 18, 2023

    Pancreatic Cancer Trial in Aurora (TTI-101)

    Not yet recruiting
    • Pancreatic Cancer
    • Aurora, Colorado
      University of Colorado
    Nov 30, 2023

    Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease Trial in Baltimore (FOLFIRINOX chemo)

    Not yet recruiting
    • Pancreatic Ductal Adenocarcinoma
    • Oligometastatic Disease
    • FOLFIRINOX chemotherapy
    • Baltimore, Maryland
      Johns Hopkins Hospital
    Nov 2, 2023

    Advanced Adenocarcinoma Trial (BA3182)

    Not yet recruiting
    • Advanced Adenocarcinoma
    • (no location specified)
    Apr 10, 2023